BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

Tesla at 320 Times Earnings: Auditing the Three Claims That Hold the Price Up

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
July 31, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

One number stops the conversation cold. Tesla’s current P/E ratio, the price a buyer pays per dollar of annual profit, sits at 320 times earnings, our data shows. That is more than double the company’s own decade median. The stock has shed more than a third of its value from its 52-week high and still carries that multiple. Something in the market’s story about Tesla has to be doing enormous work to justify it. This piece audits the three claims doing that work, one at a time, against what the filings actually say.

In one breath

Tesla’s filed numbers show revenue falling for two consecutive years and operating profit nearly evaporating, with the Q2 2026 10-Q showing an operating margin of just 1.4%. The stock price, at roughly $308, implies the market is paying for a future business, not the current one. The open question is whether the autonomous driving, robotaxi, and energy businesses can grow fast enough, and profitably enough, to make today’s price look reasonable in hindsight. That question cannot be answered from the filings alone, and that gap is the story.

Claim one: “Tesla is a growth company”

For most of its public life, this was simply true. Revenue grew more than fifty percent in fiscal 2022, and the narrative of a company doubling every few years became the foundation of the valuation. That foundation has cracked.

The 10-K for fiscal year 2025 reported full-year revenue of $94.8 billion, a 3% decline from the year before. That followed a year in which revenue was essentially flat. Two flat-to-down years in a row is not a growth company’s track record; it is a company pausing, at best, or stalling, at worst. Net income fell nearly in half, meaning the company earned roughly what a mid-sized regional bank earns, on a revenue base the size of a major airline.

BullScope TerminalTesla was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Then came Q2 2026. The Q2 2026 filing showed revenue up sharply year over year, which looks like the growth story resuming. But the comparison period was weak, and the profit picture told a different story entirely. Two years of revenue stagnation followed by a single quarter of recovery is a thin empirical foundation for a multiple of more than three hundred times earnings.

Claim two: “Margins will recover as scale kicks in”

This is the most repeated bullish argument, and the filings are the most direct test of it. Tesla’s automotive gross margin, the share of each car-sale dollar left after building the car, peaked near thirty percent in early 2022. The Q2 2026 earnings report put that figure at 16.3%, excluding regulatory credits, down meaningfully from just one quarter earlier.

The operating margin, what remains after paying for factories, engineers, and overhead, fell to 1.4% in Q2 2026. Think of it this way: on every $100 of revenue Tesla collected in the quarter, $1.40 was left as operating profit. The rest went to costs. That is not a margin structure that supports a valuation built on future earnings power, unless those margins are about to turn sharply.

Management on the Q2 2026 earnings call pointed to AI infrastructure spending and the Optimus robotics buildout as the reason. Capital expenditure guidance for full-year 2026 was raised to exceed $25 billion, roughly three times what Tesla spent on capex in all of fiscal 2025. That spending may build something valuable. But it is compressing current margins, not expanding them, and the filed numbers do not yet show the turn that the valuation assumes is coming.

The direction of profitability has been consistently downward for three years. The “margins recover at scale” thesis is a forecast, not a filed fact, a distinction the filings make plain.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Tesla and 500+ other names, on the same official data.See the evidence engine →

Claim three: “The autonomous and energy businesses change the math”

This is where the valuation lives. Wedbush analyst Dan Ives, as reported by 247 Wall St on July 27, maintains a valuation estimate nearly double where the stock trades today, anchored on FSD monetization, robotaxi networks, and Optimus scaling. The argument is that Tesla is not really a car company anymore, and pricing it like one misses the point.

The filed numbers offer a partial test. On the Q2 2026 call, management noted that a majority of North American deliveries included a Full Self-Driving subscription, which is a meaningful adoption figure. Energy gross margins, however, collapsed by roughly half in a single quarter, hit by a warranty charge and increased competition in industrial storage. That is the energy business, often cited as a high-margin growth engine, giving back gains faster than the bull case assumes.

The honest answer is that the filings cannot settle this claim. Robotaxi revenue does not yet appear as a material line item. Optimus is a cost center, not a revenue source. The autonomous business is real in the sense that FSD subscriptions exist, but it is not yet large enough to show up in the margin math in a way that explains a multiple of more than three hundred times earnings. Seven research firms, including Morgan Stanley and UBS, revised their valuation estimates downward after Q2 results, suggesting the gap between the autonomous promise and the filed reality is visible to a wide range of professional observers.

Meanwhile, a Bloomberg report on July 22 called the Cybertruck the “biggest flop in automotive history,” citing sales at a small fraction of Elon Musk’s projected annual units. That is a reminder that Tesla’s product forecasts have not always landed where management said they would, which matters when the entire valuation rests on products that do not yet exist at scale.

Reading the numbers

P/E of 320 (our data). The price-to-earnings ratio is the price tag per dollar of annual profit. At 320 times, a buyer is paying $320 for each $1 Tesla currently earns per year. A household analogy: if a rental property earns $1,000 a year in profit, a P/E of 320 would mean paying $320,000 for it. Tesla’s own decade median is 131 times, meaning the current multiple is more than twice what the market has historically paid for this company. This matters because it means the price already assumes a dramatic improvement in earnings that has not yet appeared in the filings.

BullScope TerminalYou just read Tesla’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Operating margin of 1.4% (Q2 2026 10-Q). Operating margin is what remains of each revenue dollar after paying all operating costs. At 1.4%, Tesla keeps $1.40 from every $100 of sales. For comparison, the same figure was approximately 16.8% for full-year 2022. The compression is not a rounding error; it reflects both deliberate price cuts to defend market share and a surge in spending on AI and robotics infrastructure.

Free cash flow of negative $1.09 billion (Q2 2026 10-Q). Free cash flow is the cash a business generates after paying for the investments needed to keep running and growing. Negative free cash flow means Tesla spent more cash than it brought in during the quarter. The driver was capital expenditure. With full-year 2026 capex guided above $25 billion, and the FY2025 10-K showing Tesla secured up to $30 billion in new debt facilities, the company is funding its future with borrowed money. That is a bet that the future businesses pay off. The filings show the bet being placed; they cannot show whether it wins.

Forward P/E of 167 times for 2026 (consensus via Seeking Alpha). Even using analyst forecasts for next year’s earnings, the multiple is 167 times. If earnings land at the consensus estimate of $1.78 per share for 2026, and the stock trades at its own decade-median multiple of 131 times, the implied price would be near $233. If 2027 consensus EPS of $2.22 is used at the same median multiple, the implied range rises to near $291. Those are conditional scenarios, not predictions, and they depend entirely on earnings landing at consensus and the multiple compressing to historical norms, neither of which is guaranteed.

For the standing yardsticks on Tesla: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Tesla.

Sources

  • Tesla 10-Q, Q2 2026 (SEC EDGAR)
  • Tesla 10-K, FY2025 (SEC EDGAR)
  • Tesla Q2 2026 financial results (Stock Titan)
  • Tesla Q2 2026: revenue beats amid margin pressure (Investing.com)
  • Tesla Q2 2026 earnings call transcript (Investing.com)
  • Tesla Q2 earnings call: growth over margins (Zacks)
  • Tesla earnings estimates (Seeking Alpha)
  • Wedbush $600 target, Dan Ives (247 Wall St)
  • Valuation estimate revisions after Q2 (247 Wall St)
  • Cybertruck Bloomberg report (247 Wall St)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Tesla’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Amgen: The Stock Is Priced for a Future the Filings Haven’t Promised Yet

by Moe Alsumidaie, MBA, MSF
September 8, 2026
0

For most of the past decade, Amgen was a reliable but slow-moving machine: a biotech giant that grew revenues at roughly the pace of the broader economy, collected...

Read moreDetails

A 95% Gross Margin and a P/S Below Its Own Median: PTC Therapeutics’ Profitability Flip Is Real, and the Valuation Gap Raises Questions

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

In one breath PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed. Then, in the twelve months through the fiscal...

Read moreDetails

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

Before anything else Moderna's filed revenue has fallen every year since 2022, and the company is burning through roughly $600 million a quarter. The stock, at $150.81, prices...

Read moreDetails

United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown earnings per share from $11.54 in 2020 to...

Read moreDetails

Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused to cover. Today the stock sits near $218,...

Read moreDetails
Next Post

Visa's Margin Pause: What the Latest Quarter Actually Says

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Walmart’s Math Says One Thing. The Price Tag Says Another.

August 3, 2026

Evidence Sheet: Merck & Co (MRK)

September 7, 2026

The Headline Said “Cooling.” The Data Said “Complicated.”

August 18, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.